ABVC Biopharma

ABVC Biopharma Goodwill/Assets

Goodwill to Total Assets Ratio of ABVC Biopharma (ABVC) as of Nov 22, 2026.

Goodwill/Assets

0.00

Last updated:

Goodwill to Total Assets Ratio of ABVC Biopharma is 2021 0.00 . Goodwill to Total Assets Ratio of ABVC Biopharma was 2020 0.00 . It decreases by % lower compared to the previous year.

The ABVC Biopharma Goodwill/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill/Assets
Date
Goodwill/Assets
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
The ABVC Biopharma Goodwill/Assets history
YEARGoodwill/AssetsYoY
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABVC Biopharma Stock analysis

What does ABVC Biopharma do? American BriVision (Holding) Corp. is a clinical stage biopharmaceutical company focused on developing new drugs and medical devices. It utilizes licensed technology to enhance pre-existing pharmaceutical products for cancer treatments and other diseases, with a focus on identifying responsive patients. The company operates through five compounds licensed from BioLite Inc.: ABV-1501, ABV-1502, ABV-1503, ABV-1504, and ABV-1505. As of September 30, 2016, the company had not generated any revenues from its operations. The firm's revenue model relies on the development and commercialization of its licensed compounds. It partners with BioLite Inc. for the technology and compounds, which it aims to enhance and commercialize in various markets. The company targets cancer indications and other diseases for its pharmaceutical products, seeking to identify patients who may respond to these treatments. The clinical-stage nature of its operations means it is still in the research and development phase without current revenue streams. American BriVision (Holding) Corp. is headquartered in Fremont, California, and employs 34 full-time employees. It went public via IPO on November 9, 2004. The company's focus on enhancing pre-existing drugs through licensed technology positions it for future revenue generation once its compounds reach commercialization. However, as of the latest data, it has not yet generated any revenue from its operations. ABVC Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ABVC Biopharma stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio ABVC Biopharma since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's ABVC Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ABVC Biopharma

All Key Metrics — ABVC Biopharma